Dr. Christopher Luthi

Udayan Guha is a primary care provider, practicing in Internal Medicine in New York, New York. Dr. Guha is rated as a Distinguished provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Lung Adenocarcinoma, Thymic Epithelial Tumor, EGFR Positive Lung Cancer, and Lung Cancer.

Dr. Stoopler received his Bachelor of Science degree from Tulane University in 1971 and his medical degree from Cornell University Medical College in 1975. He completed his residency at North Shore University Hospital/Memorial Hospital and his oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York City before joining the Columbia faculty in 1980. He is a Fellow of the American College of Physicians and a member of the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer, the International Society of Gastrointestinal Oncology, the American Federation for Clinical Research and the Southwest Oncology Group. Dr. Stoopler is involved in patient care, clinical research and teaching on the medical oncology service. Dr. Stoopler is rated as a Distinguished provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, Pleuropulmonary Blastoma, and Gamma Knife Radiosurgery.

Dr. Catherine Shu is the Price Family Associate Professor of Medicine and a board-certified medical oncologist specializing in the treatment of thoracic cancers, with a focus on lung cancer. She received her undergraduate degree from Princeton University, followed by her M.D. from Columbia University College of Physicians and Surgeons. After residency at Columbia University Medical Center, Dr. Shu completed her fellowship at Memorial Sloan Kettering Cancer Center, where she was appointed Chief Fellow. She currently serves as the Director of the Thoracic Medical Oncology Service. She has presented her work at numerous international conferences and has published in the top peer-reviewed oncology journals. She treats the entire spectrum of lung cancer, and has a particular interest in earlier stage and surgically resectable disease, specifically on drug combinations to help improve survival in this setting. Additionally, she runs the thoracic oncology clinical trial portfolio and devotes part of her research effort to patients with targetable mutations such as EGFR. Of all her achievements, she is proudest to be able to offer individualized and compassionate care to each and every one of her patients. She understands that each patient and family carries forth a different set of beliefs, goals, and needs. Working alongside an exceptional multidisciplinary team, she is dedicated to improving the survival and bettering the quality of life of her patients. Dr. Shu is rated as a Distinguished provider by MediFind in the treatment of Lung Adenocarcinoma. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, EGFR Positive Lung Cancer, Small Cell Lung Cancer (SCLC), and Salpingo-Oophorectomy.